目的：研究玻璃体腔注射康柏西普对黄斑水肿患者角膜厚度及内皮细胞的影响。

方法：选取2017-01/12在本院行玻璃体腔注射康柏西普治疗黄斑水肿的患者30例30眼，手术前后使用超声生物显微镜测量中央角膜厚度，使用角膜内皮计数仪测量患眼中央角膜内皮细胞密度和六角形细胞比例。

结果：本组患者术前和术后1d，1wk角膜中央厚度分别为551.68±12.80、552.06±13.22、552.49±13.83μm(P>0.05)。术前和术后1d，1wk，3、6mo中央角膜内皮细胞密度分别为2551.03±287.55、2563.79±292.34、2543.32±282.41、2526.18±280.24、2519.60±279.89个/mm²，六角形细胞比例分别为(50.23±7.51)%、(50.93±8.23)%、(50.60±7.91)%、(50.40±7.50)%、(50.93±8.19)%，均无明显差异(P>0.05)。

结论：玻璃体腔注射康柏西普是一种安全的治疗黄斑水肿的方法，在注射后6mo内对角膜厚度及内皮细胞无明显影响。

METHODS:Intravitreal conbercept was performed on 30 eyes of 30 patients with macular edema due to different diseases from Jan. 2017 to Dec. 2017 in our hospital. The central corneal thickness was identified by ultrasonic biomicroscope(UBM)before and after surgery. Specular microscopy was also used to detect the density of central corneal endothelial cells and proportion of hexagonal cells before and after surgery.

RESULTS:The central corneal thickness were 551.68±12.80μm before surgery, 552.06±13.22μm at the first day after surgery and 552.49±13.83μm at 1wk after surgery(P>0.05). The density of central corneal were 2551.03±287.55/mm² before surgery, and 2563.79±292.34, 2543.32±282.41, 2526.18±280.24, 2519.60±279.89/mm² at 1d, 1wk, 3mo and 6mo after surgery respectively, meanwhile, the proportion of hexagonal cells were(50.23±7.51)% before surgery, and(50.93±8.23)%,(50.60±7.91)%,(50.40±7.50)%,(50.93±8.19)% at 1d, 1wk, 3mo and 6mo after surgery respectively(P>0.05).

CONCLUSION: Intravitreal injections of conbercept demonstrated a safety in the treatment of macular edema. It seems no affects on corneal thickness and corneal endothelial cells at 6mo after intravitreal conbercept.